Literature DB >> 30876862

Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain.

Dušan Garić1, Juan B De Sanctis2, Juhi Shah3, Daciana Catalina Dumut4, Danuta Radzioch5.   

Abstract

Ceramides, the principal building blocks of all sphingolipids, have attracted the attention of many scientists around the world interested in developing treatments for cystic fibrosis, the most common genetic disease of Caucasians. Many years of fruitful research in this field have produced some fundamentally important, yet controversial results. Here, we aimed to summarize the current knowledge on the role of long- and very-long- chain ceramides, the most abundant species of ceramides in animal cells, in cystic fibrosis and other diseases. We also aim to explain the importance of the length of their side chain in the context of stability of transmembrane proteins through a concise synthesis of their biophysical chemistry, cell biology, and physiology. This review also addresses several remaining riddles in this field. Finally, we discuss the technical challenges associated with the analysis and quantification of ceramides. We provide the evaluation of the antibodies used for ceramide quantification and we demonstrate their lack of specificity. Results and discussion presented here will be of interest to anyone studying these enigmatic lipids.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30876862     DOI: 10.1016/j.plipres.2019.03.001

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  6 in total

1.  Efficacy of Optimized Treatment Protocol Using LAU-7b Formulation against Ovalbumin (OVA) and House Dust Mite (HDM) -Induced Allergic Asthma in Atopic Hyperresponsive A/J Mice.

Authors:  Mina Youssef; Juan B De Sanctis; Cynthia Kanagaratham; Shao Tao; Eisha Ahmed; Danuta Radzioch
Journal:  Pharm Res       Date:  2020-01-08       Impact factor: 4.200

2.  Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis.

Authors:  Hamed Horati; Hettie M Janssens; Camilla Margaroli; Mieke Veltman; Marta Stolarczyk; Matthew B Kilgore; Jeffrey Chou; Limin Peng; Harm A M W Tiddens; Joshua D Chandler; Rabindra Tirouvanziam; Bob J Scholte
Journal:  J Cyst Fibros       Date:  2020-02-10       Impact factor: 5.482

3.  Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis.

Authors:  Aaron I Gardner; Iram J Haq; A John Simpson; Katrin A Becker; John Gallagher; Vinciane Saint-Criq; Bernard Verdon; Emily Mavin; Alexandra Trigg; Michael A Gray; Albert Koulman; Melissa J McDonnell; Andrew J Fisher; Elizabeth L Kramer; John P Clancy; Christopher Ward; Edward H Schuchman; Erich Gulbins; Malcolm Brodlie
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

4.  Neutral Ceramidase Is Required for the Reproduction of Brown Planthopper, Nilaparvata lugens (Stål).

Authors:  Xiao-Xiao Shi; Mu-Fei Zhu; Ni Wang; Yuan-Jie Huang; Min-Jing Zhang; Chao Zhang; Soomro A Ali; Wen-Wu Zhou; Chuanxi Zhang; Cungui Mao; Zeng-Rong Zhu
Journal:  Front Physiol       Date:  2021-02-24       Impact factor: 4.566

5.  Enhanced inflammasome activation and reduced sphingosine-1 phosphate S1P signalling in a respiratory mucoobstructive disease model.

Authors:  Hai B Tran; Matthew G Macowan; Adrian Abdo; Martin Donnelley; David Parsons; Sandra Hodge
Journal:  J Inflamm (Lond)       Date:  2020-04-21       Impact factor: 4.981

6.  Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs.

Authors:  Asmahan Abu-Arish; Elvis Pandžić; Yishan Luo; Yukiko Sato; Mark J Turner; Paul W Wiseman; John W Hanrahan
Journal:  J Cell Sci       Date:  2022-03-07       Impact factor: 5.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.